Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

ROXY proteins help plants respond to nitrate shortage by affecting nutrient sensing and growth.

PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

Both enzyme forms can sulfate minoxidil.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

RUM-loaded SLN shows promise for treating acne and hair loss topically.

Perhexiline can effectively target ovarian cancer cells left after treatment.

PLD is an effective and safer alternative for treating breast cancer.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.